PPI therapy: When to worry about fracture risk

,

Applied Evidence

PPI therapy: When to worry about fracture risk

J Fam Pract. 2011 May;60(5):255-260

PDF Download

References

1. Bartholow M. Top 200 prescription drugs of 2009. May 11, 2010. Pharmacy Times. Available at: http://www.pharmacytimes. http://www.pharmacytimes.com/publications/issue/2010/May2010/RxFocusTopDrugs-0510. Accessed April 8, 2011.

2. US Food and Drug Administration. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. May 25, 2010; March 23, 2011 update. Available at: http://www.fda.gov/Drugs/DrugSafety/postmarketdrugsafetyInformationforpatientsandproviders/ucm213206.htm#SafetyAnnouncement. Accessed March 24, 2011.

3. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953.

4. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83.

5. Targownik LE, Lix LM, Metge CJ. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319-326.

6. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139:93-101.

7. Targownik LE, Lix LM, Leung S, et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138:896-904.

8. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951-959.

9. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251-259.

10. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73:640-647.

11. Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H+-ATPase. Curr Pharm Des. 2002;8:2033-2048.

12. Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(suppl 2):S2-S4.

13. Gray SL, LaCroix AZ, Larson L, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women. Arch Intern Med. 2010;170:765-771.

14. Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol. 2009;104(suppl 2):S21-S26.

15. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol.;2009;104(suppl 2):S27-S32.

16. National Digestive Diseases Information Clearinghouse. Heartburn, gastroesophageal reflux (GER), and gastroesophageal reflux disease (GERD). Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/gerd. Accessed April 18, 2011.